ACTA1 and liver disorder: In addition, in a preclinical rat model of thioacetamide-induced nodularity, hepatic fibrosis, portal hypertension and portosystemic shunts, BI 685509 reduced Sirius red morphometry (SRM) by 38%, alpha-smooth muscle actin (αSMA)-positive area by 55%, portal pressure by 26% and portal shunt by 10%; hence, it could be used as a potential treatment for cirrhosis-associated portal hypertension (Jones et al., 2023).